SMAC mimetics overcome apoptotic resistance in ovarian cancer through MSLN-TNF alpha axis
Coelho, R.; Seashore-Ludlow, B.; Schutz, S.; Christopher Lombardo, F.; Moussaud-Lamodiere, E.; Casanova, R.; Ficek-Pascual, J.; Brunhilde Labrosse, K.; Hensle, M.; Lopez-Nunez, M.; Rimmer, N.; Fedier, A.; Lima, R.; Montavon Sartorius, C.; Kurzeder, C.; Singer, F.; Bertolini, A.; The TumorProfiler Consortium, ; Fucikova, J.; Ratsch, G.; Bodenmiller, B.; Kallioniemi, O.; Ostling, P.; David, L.; Heinzelmann-Schwarz, V.; Jacob, F.
Show abstract
Resistance to chemotherapy and PARPi inhibitors remains a critical challenge in the treatment of epithelial ovarian cancer, mainly due to disabled apoptotic responses in tumor cells. Given mesothelins pivotal role in ovarian cancer and its restricted expression in healthy tissues, we conducted a drug-screening discovery analysis across a range of genetically modified cancer cells to unveil mesothelins therapeutic impact. We observed enhanced cell death in cancer cells with low mesothelin expression when exposed to a second mitochondria-derived activator of caspases (SMAC) mimetics, and demonstrated a compelling synergy when combined with chemotherapy in ex vivo patient-derived cultures and zebrafish tumor xenografts. Mechanistically, the addition of the SMAC mimetics drug birinapant to either carboplatin or paclitaxel triggered the activation of the Caspase 8-dependent apoptotic program facilitated by TNFLJ signaling. Multimodal analysis of neoadjuvant-treated patient samples further revealed an association between tumor-associated macrophages and the activation of TNFLJ-related pathways. Our proposed bimodal treatment shows promise in enhancing the clinical management of patients by harnessing the potential of SMAC mimetics alongside conventional chemotherapy.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death 97%
- Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1 96%
- Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype 96%
Similar papers in this journal
- Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting 97%
- An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer 96%
- Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer 96%
Similar papers in this journal
- Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response 96%
- FSTL3 is a biomarker of poor prognosis and is associated with immunotherapy resistance in ovarian cancer. 95%
- Metabolic breakdown of non-small cell lung cancers by mitochondrial HSPD1 targeting 95%
Similar papers in this journal
- WNT inhibition creates a BRCA-like state in Wnt-addicted cancer 96%
- Exploiting a metabolic vulnerability in brain tumour stem cells using a brain-penetrant drug with safe profile 96%
- DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells. 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.